Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

7.40USD
3:59pm EST
Change (% chg)

$-0.30 (-3.90%)
Prev Close
$7.70
Open
$7.70
Day's High
$7.80
Day's Low
$7.35
Volume
367,395
Avg. Vol
268,839
52-wk High
$15.35
52-wk Low
$4.10

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.24
Market Cap(Mil.): $544.02
Shares Outstanding(Mil.): 70.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-TG Therapeutics qtrly net loss per common share $0.48

* TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results

Nov 08 2017

BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101

* TG Therapeutics Inc - ‍announced results from phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of multiple sclerosis​

Oct 26 2017

BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial

* TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial

Oct 16 2017

BRIEF-TG Therapeutics announces completion of target enrollment

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial

Sep 05 2017

BRIEF-TG Therapeutics announces successful outcome from first pre-planned interim analysis

* TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial

Aug 10 2017

BRIEF-TG Therapeutics Q2 loss per share ‍$0.45​

* Tg therapeutics Inc provides business update and reports second quarter 2017 financial results

Aug 09 2017

BRIEF-TG therapeutics provides FDA update on multiple sclerosis study

* Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS)

Aug 01 2017

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

Jun 15 2017

BRIEF-TG Therapeutics says follow-up data for combination of TGR-1202 plus Ibrutinib

* TG Therapeutics, Inc. Announces follow-up data for combination of TGR-1202 (umbralisib) plus ibrutinib in patients with relapsed or refractory cll and mcl at the 14th international conference on malignant lymphoma

Jun 14 2017

Wall Street dips; 2017's laggards tick up, Apple slips

NEW YORK Stocks dipped on Wall Street on Monday as a drop in Apple partly offset gains in energy and financial stocks, some of the market's worst-performing sectors so far this year.

Jun 05 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.34 +0.41
Novartis AG (NOVN.S) CHF83.55 +0.45
Roche Holding Ltd. (ROG.S) CHF244.00 +0.40
Roche Holding Ltd. (RO.S) CHF245.60 -0.40
Merck & Co., Inc. (MRK.N) $54.27 +0.17
Bayer AG (BAYGn.DE) €109.65 +1.00
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.44 +0.69
Abbott Laboratories (ABT.N) $56.12 +0.83
Alexion Pharmaceuticals, Inc. (ALXN.OQ) $108.05 -0.44

Earnings vs. Estimates